Abstract
Many cancers of the gastrointestinal tract are treated with chemotherapy, radiation, and surgery. Chemotherapy is often used as a radiation sensitizer amplifying both the therapeutic effect and the toxicity of radiation. Since anal and rectal cancer treatment may require radiation to the perianal skin, this chapter focuses on these two disease entities and the management of associated skin toxicity. Nonetheless, these methods can be extended to other sites in the management of gastrointestinal malignancies where skin reactions may occur.
Chemoradiation for anal cancer may involve the use of 5-fluorouracil (5-FU) and mitomycin C (MMC), a regimen, when used in combination with radiation therapy, is known to cause skin toxicity. In addition, HIV-positive patients with anal cancer require special attention. Those with low CD4 counts have an increased risk of skin toxicity, infection, and poor healing. Radiation therapy alone, or with weekly chemotherapy, can be considered for these patients, depending on their comorbidities.
Rectal cancer patients also undergo chemoradiation, but several factors contribute to lower toxicity in these patients compared to anal cancer patients: (1) chemotherapy is single-agent 5-FU, (2) the radiation dose is lower since patients will be getting surgery after to remove the tumor, and (3) due to the location within the deep pelvis, radiation fields do not typically extend to the skin. Nonetheless, these patients can also exhibit skin toxicities, and management of these toxicities is similar.
For the management of skin toxicity in anal and rectal cancer patients undergoing radiation, planning for skin toxicity must be incorporated into treatment. We recommend examining the skin dose closely and placing film dosimeters at first treatment, managing gastrointestinal toxicity as diarrhea can cause irritation of skin, and providing patients with a nutrition consult prior to therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Surveillance, Epidemiology, and End Results Program, Cancer Statistics Review 1975–2012. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. 2015. http://seer.cancer.gov/csr/1975_2012/results_single/sect_01_table.01.pdf. Accessed 26 June 2015.
Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer. 2004;101:281–8. doi:10.1002/cncr.20364.
Cancer Facts and Figures 2015. American Cancer Society. 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed 29 April 2015.
Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10.
Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–9.
Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, Houghton J, et al. Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049–54.
Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.
Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson 3rd AB, Thomas Jr CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21. doi:10.1001/jama.299.16.1914.
John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92–08. Cancer J Sci Am. 1996;2:205–11.
James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol. 2009;27.
Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8. doi:10.1038/sj.bjc.6605605.
Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson 3rd AB, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–51. doi:10.1200/JCO.2012.43.8085.
Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119:2973–80. doi:10.1002/cncr.28045.
Deutsch E, Lemanski C, Paris E, Delarochefordiere A, Martel-Lafay I, Rio E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. J Clin Oncol. 2011;29.
Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26:474–9. doi:10.1200/JCO.2007.14.2810.
Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009;75:143–9. doi:10.1016/j.ijrobp.2008.10.046.
Oehler-Janne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26:2550–7. doi:10.1200/JCO.2007.15.2348.
Klencke BJ, Palefsky JM. Anal cancer: an HIV-associated cancer. Hematol Oncol Clin North Am. 2003;17:859–72.
Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127–31.
Fraunholz I, Weiss C, Eberlein K, Haberl A, Rodel C. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys. 2010;76:1425–32. doi:10.1016/j.ijrobp.2009.03.060.
Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63:354–61. doi:10.1016/j.ijrobp.2005.02.030.
Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2010;78:1413–9. doi:10.1016/j.ijrobp.2009.09.046.
Kachnic L, Winter K, Myerson R, Goodyear M, Willins J, Esthappan J, et al. RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-Fluorouracil and Mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2009;75:5. doi:10.1016/j.ijrobp.2009.07.038.
Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33. doi:10.1016/j.ijrobp.2012.09.023.
Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1981–7. doi:10.1016/j.ijrobp.2011.01.051.
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23. doi:10.1002/bjs.5506.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Anwar, M., Bohm, J. (2016). Gastrointestinal Cancer. In: Fowble, B., Yom, S., Yuen, F., Arron, S. (eds) Skin Care in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-31460-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-31460-0_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-31458-7
Online ISBN: 978-3-319-31460-0
eBook Packages: MedicineMedicine (R0)